SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01670396

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

G Protein β3 Subunit (GNB3) Polymorphism and Restenosis of Coronary Drug-eluting Stents

The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).

NCT01670396 Coronary Artery Disease
MeSH:Coronary Artery Disease
HPO:Coronary artery atherosclerosis


Primary Outcomes

Measure: In-stent restenosis

Time: 6-24months after stent implanting

Secondary Outcomes

Measure: target lesion revascularization (TLR)

Time: 6-24months after stent implanting

Measure: re-myocardial infarction

Time: 6-24months after stent implating

Time Perspective: Retrospective

Case Control


There is one SNP

SNPs


1 C825T

The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins. --- C825T ---



HPO Nodes


HPO: